NZ233250A - Piperazine derivatives and pharmaceutical compositions - Google Patents
Piperazine derivatives and pharmaceutical compositionsInfo
- Publication number
- NZ233250A NZ233250A NZ233250A NZ23325090A NZ233250A NZ 233250 A NZ233250 A NZ 233250A NZ 233250 A NZ233250 A NZ 233250A NZ 23325090 A NZ23325090 A NZ 23325090A NZ 233250 A NZ233250 A NZ 233250A
- Authority
- NZ
- New Zealand
- Prior art keywords
- piperazine
- compound
- compounds
- general formula
- injection
- Prior art date
Links
- 150000004885 piperazines Chemical class 0.000 title claims description 10
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 38
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- CAWHJQAVHZEVTJ-UHFFFAOYSA-N methylpyrazine Chemical class CC1=CN=CC=N1 CAWHJQAVHZEVTJ-UHFFFAOYSA-N 0.000 claims description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- BUHYMJLFRZAFBF-UHFFFAOYSA-N 3,4,5-trimethoxybenzoyl chloride Chemical compound COC1=CC(C(Cl)=O)=CC(OC)=C1OC BUHYMJLFRZAFBF-UHFFFAOYSA-N 0.000 claims description 3
- 239000003610 charcoal Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 229910052801 chlorine Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 208000009079 Bronchial Spasm Diseases 0.000 claims 3
- 208000014181 Bronchial disease Diseases 0.000 claims 3
- 206010006482 Bronchospasm Diseases 0.000 claims 3
- 241000700159 Rattus Species 0.000 claims 2
- 241000700198 Cavia Species 0.000 claims 1
- 241000700199 Cavia porcellus Species 0.000 claims 1
- 244000093965 Triphasia trifolia Species 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001143 conditioned effect Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 18
- LSXKDWGTSHCFPP-UHFFFAOYSA-N 1-bromoheptane Chemical compound CCCCCCCBr LSXKDWGTSHCFPP-UHFFFAOYSA-N 0.000 description 14
- 101150041968 CDC13 gene Proteins 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 239000005662 Paraffin oil Substances 0.000 description 9
- 239000013078 crystal Substances 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 125000001680 trimethoxyphenyl group Chemical group 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 4
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- -1 mono methoxyphenyl Chemical group 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 3
- MYNRDUPGBPOWQT-IDTAVKCVSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-[[3-hydrazinylpropyl(methyl)amino]methyl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CN(CCCNN)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MYNRDUPGBPOWQT-IDTAVKCVSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- IAZCKSJRRRXZEY-UHFFFAOYSA-N 1-(2-bromoethyl)-4-methylbenzene Chemical compound CC1=CC=C(CCBr)C=C1 IAZCKSJRRRXZEY-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- CQWYAXCOVZKLHY-UHFFFAOYSA-N 1-bromo-2,2-dimethylpropane Chemical compound CC(C)(C)CBr CQWYAXCOVZKLHY-UHFFFAOYSA-N 0.000 description 1
- WSULSMOGMLRGKU-UHFFFAOYSA-N 1-bromooctadecane Chemical compound CCCCCCCCCCCCCCCCCCBr WSULSMOGMLRGKU-UHFFFAOYSA-N 0.000 description 1
- KOFZTCSTGIWCQG-UHFFFAOYSA-N 1-bromotetradecane Chemical compound CCCCCCCCCCCCCCBr KOFZTCSTGIWCQG-UHFFFAOYSA-N 0.000 description 1
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 1
- FEETYXHKBJPSNJ-UHFFFAOYSA-N 2-(3,3-dimethylbutyl)pyrazine Chemical compound CC(C)(C)CCC1=CN=CC=N1 FEETYXHKBJPSNJ-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 1
- VINAAOAOAAFWTL-UHFFFAOYSA-N 2-octylpiperazine Chemical compound CCCCCCCCC1CNCCN1 VINAAOAOAAFWTL-UHFFFAOYSA-N 0.000 description 1
- VEIAXROYVVCIER-UHFFFAOYSA-N 2-octylpyrazine Chemical compound CCCCCCCCC1=CN=CC=N1 VEIAXROYVVCIER-UHFFFAOYSA-N 0.000 description 1
- ZYLOSYQBUIVRNC-UHFFFAOYSA-N 2-pentadecylpiperazine Chemical compound CCCCCCCCCCCCCCCC1CNCCN1 ZYLOSYQBUIVRNC-UHFFFAOYSA-N 0.000 description 1
- WLXHHSGICQMPRB-UHFFFAOYSA-N 2-pentylpiperazine Chemical compound CCCCCC1CNCCN1 WLXHHSGICQMPRB-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 101001001462 Homo sapiens Importin subunit alpha-5 Proteins 0.000 description 1
- 102100036186 Importin subunit alpha-5 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
- XNHVKMBOUXNOTB-UHFFFAOYSA-N [3-nonadecyl-4-(3,4,5-trimethoxybenzoyl)piperazin-1-yl]-(3,4,5-trimethoxyphenyl)methanone Chemical compound CCCCCCCCCCCCCCCCCCCC1CN(C(=O)C=2C=C(OC)C(OC)=C(OC)C=2)CCN1C(=O)C1=CC(OC)=C(OC)C(OC)=C1 XNHVKMBOUXNOTB-UHFFFAOYSA-N 0.000 description 1
- SKSMQXCVXPZADQ-UHFFFAOYSA-N [3-octyl-4-(3,4,5-trimethoxybenzoyl)piperazin-1-yl]-(3,4,5-trimethoxyphenyl)methanone Chemical compound CCCCCCCCC1CN(C(=O)C=2C=C(OC)C(OC)=C(OC)C=2)CCN1C(=O)C1=CC(OC)=C(OC)C(OC)=C1 SKSMQXCVXPZADQ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- JYPVVOOBQVVUQV-CGHBYZBKSA-N angiotensinamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 JYPVVOOBQVVUQV-CGHBYZBKSA-N 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- UUWSLBWDFJMSFP-UHFFFAOYSA-N bromomethylcyclohexane Chemical compound BrCC1CCCCC1 UUWSLBWDFJMSFP-UHFFFAOYSA-N 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000000742 histaminergic effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 102000030769 platelet activating factor receptor Human genes 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898908587A GB8908587D0 (en) | 1989-04-15 | 1989-04-15 | New 2-substituted n,n'-ditrimethoxybenzoyl piperazines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ233250A true NZ233250A (en) | 1991-03-26 |
Family
ID=10655129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ233250A NZ233250A (en) | 1989-04-15 | 1990-04-09 | Piperazine derivatives and pharmaceutical compositions |
Country Status (32)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5344830A (en) * | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
| IL111730A (en) * | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same |
| US5883098A (en) * | 1993-11-29 | 1999-03-16 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
| US5610165A (en) * | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
| US5795894A (en) * | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| ES2197238T3 (es) * | 1995-05-02 | 2004-01-01 | Schering Corporation | Derivados de piperazina como antagonistas de neuroquininas. |
| US5892039A (en) * | 1995-08-31 | 1999-04-06 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| BR9610277A (pt) * | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
| US5869488A (en) * | 1996-05-01 | 1999-02-09 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| FR2780649B1 (fr) | 1998-07-06 | 2001-03-09 | Univ Paris Vii Denis Diderot | Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1243991A (en) * | 1968-06-10 | 1971-08-25 | Ici Ltd | Piperidine, morpholine and piperazine derivatives |
| FR2209560A1 (en) * | 1972-12-07 | 1974-07-05 | Degussa | N-(Trialkoxyaroyl)-ethylenediamine derivs - useful as cardioactive medicaments, exhibit anti-ischaemic activity comparable to nitroglycerin |
| IL85700A0 (en) * | 1987-03-24 | 1988-08-31 | Takeda Chemical Industries Ltd | 1,4-disubstituted piperazine compounds,their production and use |
| EP0318235A3 (en) * | 1987-11-25 | 1991-05-02 | Takeda Chemical Industries, Ltd. | Paf antagonist, 1,4-disubstituted piperazine compounds and production thereof |
| KR900018073A (ko) * | 1988-05-23 | 1990-12-20 | 추후보충 | 피페라진 화합물 |
| GB8823775D0 (en) * | 1988-10-11 | 1988-11-16 | Scras | New 2-carbonyl substituted n n'-di-(trimethoxybenzoyl)piperazines |
| GB8823776D0 (en) * | 1988-10-11 | 1988-11-16 | Scras | New 2-methoxycarbonyl sustituted n n'-di-(trimethoxybenzoyl)piperazines |
| US4997836A (en) * | 1988-11-11 | 1991-03-05 | Takeda Chemical Industries, Ltd. | Trisubstituted piperazine compounds, their production and use |
-
1989
- 1989-04-15 GB GB898908587A patent/GB8908587D0/en active Pending
-
1990
- 1990-04-03 ZA ZA902566A patent/ZA902566B/xx unknown
- 1990-04-04 GB GB9007612A patent/GB2230262B/en not_active Expired - Lifetime
- 1990-04-05 NL NL9000798A patent/NL9000798A/nl not_active Application Discontinuation
- 1990-04-05 IN IN140DE1990D patent/IN175799B/en unknown
- 1990-04-06 SE SE9001269A patent/SE505186C2/sv not_active IP Right Cessation
- 1990-04-06 GR GR900100270A patent/GR1000355B/el unknown
- 1990-04-09 NZ NZ233250A patent/NZ233250A/en unknown
- 1990-04-09 US US07/506,421 patent/US5019576A/en not_active Expired - Lifetime
- 1990-04-10 MA MA22064A patent/MA21805A1/fr unknown
- 1990-04-10 AR AR90316593A patent/AR247736A1/es active
- 1990-04-10 CH CH1206/90A patent/CH681301A5/fr not_active IP Right Cessation
- 1990-04-10 NO NO901631A patent/NO176098C/no unknown
- 1990-04-10 LU LU87719A patent/LU87719A1/fr unknown
- 1990-04-11 ES ES9001056A patent/ES2019554A6/es not_active Expired - Lifetime
- 1990-04-11 AT AT0086690A patent/AT399337B/de not_active IP Right Cessation
- 1990-04-11 DZ DZ900066A patent/DZ1407A1/fr active
- 1990-04-11 BE BE9000408A patent/BE1007245A3/fr not_active IP Right Cessation
- 1990-04-11 IE IE131490A patent/IE65058B1/en not_active IP Right Cessation
- 1990-04-11 DK DK091890A patent/DK91890A/da unknown
- 1990-04-11 PT PT93736A patent/PT93736B/pt not_active IP Right Cessation
- 1990-04-12 TN TNTNSN90051A patent/TNSN90051A1/fr unknown
- 1990-04-12 OA OA59775A patent/OA09446A/xx unknown
- 1990-04-12 FI FI901883A patent/FI92058C/fi not_active IP Right Cessation
- 1990-04-12 DE DE4011925A patent/DE4011925A1/de not_active Ceased
- 1990-04-12 IT IT20020A patent/IT1241631B/it active IP Right Grant
- 1990-04-12 CA CA002014521A patent/CA2014521C/en not_active Expired - Fee Related
- 1990-04-13 FR FR909004798A patent/FR2645859B1/fr not_active Expired - Lifetime
- 1990-04-13 FR FR909004797A patent/FR2645743B1/fr not_active Expired - Lifetime
- 1990-04-13 JP JP2096620A patent/JP2633709B2/ja not_active Expired - Lifetime
- 1990-04-14 KR KR1019900005198A patent/KR900016178A/ko not_active Ceased
- 1990-04-17 AU AU53261/90A patent/AU631334B2/en not_active Ceased
-
1992
- 1992-09-11 SG SG920/92A patent/SG92092G/en unknown
- 1992-11-26 HK HK950/92A patent/HK95092A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Artis et al. | Oxidative radical cyclization of (. omega.-iodoalkyl) indoles and pyrroles. synthesis of (-)-monomorine and three diastereomers | |
| EP1641763A2 (fr) | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1 | |
| NZ233250A (en) | Piperazine derivatives and pharmaceutical compositions | |
| KR100388568B1 (ko) | 피리미디닐피라졸유도체와이의염및이를포함하는항종양제 | |
| EP1716142A2 (fr) | Derives d'oxazole, leur preparation et leur utilisation en therapeutique | |
| CA1310966C (en) | Substituted 1-(h-imidazol-4-yl)alkyl-benzamides | |
| US5486518A (en) | 4-indolylpiperazinyl derivatives | |
| FI63226B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1-difenylmetyl-3-metyl-3-bensylpiperazinderivat | |
| FI67544C (fi) | Foerfarande foer framstaellning av farmakologiskt vaerdefullt imidazolinderivat | |
| EP1678159A2 (fr) | Derives de thiophene-2-carboxamide et leurs utilisation comme antagonistes des recepteurs cb1 des cannabinoides | |
| US5091393A (en) | Tertiary 2,5-dialkyl-3-phenylpiperidine derivatives having opiate-antagonistic activity | |
| CA1320958C (en) | 2-carbonyl substituted n,n'-di-(trimethoxybenzoyl) piperazines, process for preparing the same and therapeutical compounds containing them | |
| Gupton et al. | The application of vinylogous iminium salts and related synthons to the regiocontrolled preparation of 2, 3-and 2, 5-disubstituted pyrroles | |
| US4156730A (en) | Pharmaceutically active compounds, preparation thereof, intermediates useful in such preparation and compositions containing the compounds | |
| FI89357C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara benso- och cyklohepta/1,2-c;3,4-c'/dipyrazolderivat | |
| US4927825A (en) | 2-methoxycarbonyl substituted N,N'-di-(trimethoxybenzoyl) piperazines, process for preparing the same and therapeutical compounds containing them | |
| Pocar et al. | v‐Triazolines. XXXIX. 1, 2, 4‐Triaryl‐3‐aminopyrroles. Unusual Reaction Products in the Pyrolysis of 5‐Amino‐v‐triazolines and the Crystal Structure of 2‐(3‐Morpholin‐4‐yl‐2, 4‐pyrrol‐1‐yl) benzonitrile | |
| FI94760C (fi) | Menetelmä terapeuttisesti käyttökelpoisten pyrrolo/2,3-b/indoliketonijohdannaisten valmistamiseksi | |
| Földényi et al. | Heterocyclic derivatives of 2-amino-4-nitrophenol | |
| CA2012656A1 (en) | Preparation and use of pyridinyl-1-pyrazole-1-alkanamides as antiarrhythmic agents | |
| EP2222308A1 (en) | N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors | |
| Dulenko et al. | Recyclization of indolo [2, 3-c] pyrylium salts by reaction with secondary amines |